What is HC Wainwright’s Forecast for CRVS FY2030 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a research note issued on Friday, March 13th. HC Wainwright analyst S. Lee anticipates that the company will earn $0.83 per share for the year. HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share.

Other equities research analysts also recently issued reports about the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 price objective (up from $32.00) on shares of Corvus Pharmaceuticals in a research report on Friday, March 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Friday. Mizuho set a $30.00 target price on Corvus Pharmaceuticals in a research note on Thursday, January 29th. Wall Street Zen lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Jefferies Financial Group increased their price target on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Corvus Pharmaceuticals Price Performance

Shares of CRVS stock opened at $15.45 on Monday. The firm has a 50-day moving average of $16.81 and a 200-day moving average of $10.75. Corvus Pharmaceuticals has a one year low of $2.54 and a one year high of $26.95. The company has a market cap of $1.30 billion, a P/E ratio of -30.90 and a beta of 0.78.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01).

Institutional Investors Weigh In On Corvus Pharmaceuticals

Large investors have recently modified their holdings of the stock. Quarry LP purchased a new position in shares of Corvus Pharmaceuticals during the third quarter valued at about $27,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Corvus Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock worth $28,000 after buying an additional 748 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in Corvus Pharmaceuticals during the 2nd quarter valued at approximately $49,000. Russell Investments Group Ltd. bought a new stake in Corvus Pharmaceuticals during the 3rd quarter valued at approximately $49,000. Finally, Sender Co & Partners Inc. purchased a new position in shares of Corvus Pharmaceuticals during the 2nd quarter worth approximately $52,000. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.